Proclemer A, Facchin D, Pagnutti C, Fioretti P, De Michele C
Istituto di Cardiologia, Fondazione IRCAB, Udine, Italy.
Pacing Clin Electrophysiol. 2000 Jun;23(6):998-1002. doi: 10.1111/j.1540-8159.2000.tb00887.x.
RF current delivery may cause acute and chronic dysfunction of previously implanted pacemakers. The aim of this study was to assess prospectively the effects of RF energy on Thera I and Kappa pacemakers in 70 consecutive patients (mean age 70 +/- 11 years, mean left ventricular ejection fraction 48 +/- 15%) who underwent RF ablation of the AV junction for antiarrhythmic drug refractory atrial fibrillation (permanent in 42 patients, paroxysmal in 28). These pacing systems incorporate protection elements to avoid electromagnetic interference. The pacemakers (Thera DR 7960 I in 20 patients, Thera SR 8960 I in 30, Kappa DR 600-601 in 8, Kappa SR 700-701 in 12) were implanted prior to RF ablation in a single session procedure and were transiently programmed to VVI mode at a rate of 30 beats/min. Capsure SP and Z unibipolar leads were used. During RF application there was continuous monitoring of three ECG leads, endocavitary electrograms, and event markers. Complete AV block was achieved in all cases after 3.6 +/- 2.9 RF pulses and 100 +/- 75 seconds of RF energy delivery. The mean time of pacemaker implantation and RF ablation was 60 +/- 20 minutes. Transient or permanent pacemaker dysfunction including under/oversensing, reversion to a "noise-mode" pacing, pacing inhibition, reprogramming, or recycling were not observed. Leads impedance, sensing, and pacing thresholds remained in the normal range in the acute and long-term phase (average follow-up 18 +/- 12 months). In conclusion, Thera I and Kappa pacemakers exhibit excellent protection against interference produced by RF current. The functional integrity of the pacemakers and Capsure leads was observed in the acute and chronic phases. Thus, the implantation of these pacing systems prior to RF ablation of the AV junction can be recommended.
射频电流传输可能导致先前植入的起搏器出现急性和慢性功能障碍。本研究的目的是前瞻性评估射频能量对70例连续患者(平均年龄70±11岁,平均左心室射血分数48±15%)的Thera I和Kappa起搏器的影响,这些患者因抗心律失常药物难治性心房颤动(42例为永久性,28例为阵发性)接受了房室结射频消融术。这些起搏系统包含保护元件以避免电磁干扰。起搏器(20例为Thera DR 7960 I,30例为Thera SR 8960 I,8例为Kappa DR 600 - 601,12例为Kappa SR 700 - 701)在射频消融术前单次手术中植入,并临时程控为VVI模式,频率为30次/分钟。使用了Capsure SP和Z单极导线。在射频应用期间,持续监测三条心电图导联、心腔内电图和事件标记。在3.6±2.9次射频脉冲和100±75秒的射频能量传输后,所有病例均实现了完全性房室传导阻滞。起搏器植入和射频消融的平均时间为60±20分钟。未观察到短暂或永久性起搏器功能障碍,包括感知不足/过度感知、恢复到“噪声模式”起搏、起搏抑制、重新程控或重置。在急性期和长期阶段(平均随访18±12个月),导线阻抗、感知和起搏阈值均保持在正常范围内。总之,Thera I和Kappa起搏器对射频电流产生的干扰表现出优异的保护作用。在急性期和慢性期均观察到起搏器和Capsure导线的功能完整性。因此,推荐在房室结射频消融术前植入这些起搏系统。